This study assesses comparative resource use for patients given a new diagnosis of nonvalvular atrial fibrillation treated with dabigatran or warfarin in a real-world setting.
Matthew Sussman, MA
Advertisement
Articles by Matthew Sussman, MA
An incidence-based model was developed to estimate the annual ischemic and hemorrhagic stroke–related healthcare costs to a hypothetical US health plan with 1 million enrollees.
Advertisement
Latest Updated Articles
- Annual Stroke Costs to Health Plans Among Atrial Fibrillation Patients
Published: June 17th 2015 | Updated:
- Resource Use Among Nonvalvular Atrial Fibrillation Patients
Published: October 19th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
4
Interim Phase 2 IOV-LUNG-202 Data Show Lifileucel’s Potential Treating Advanced NSCLC
5
